English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, July 31, 2019
エーザイ、E2082の臨床第I相試験(治験)における死亡例の発生について
Tuesday, July 23, 2019
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA
Monday, June 10, 2024
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
エーザイとバイオジェン、早期アルツハイマー病治療剤「レケンビ(R)」の静注維持投与に関する生物製剤承認一部変更申請が米国FDAにより受理
Monday, June 3, 2024
Eisai Named to List of The Time 100 Most Influential Companies
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform
エーザイ、TIME 誌による「最も影響力のある 100 社(TIME100 MOST INFLUENTIAL COMPANIES)」に選定
エーザイ、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向けたベンチャー投資事業を強化
Tuesday, May 28, 2024
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
Thursday, May 23, 2024
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575